PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27498816-5 2016 The patient visited the hospital because of gait disturbances and DAT-scan showed a levodopa transducer decrease in the putamen. Levodopa 84-92 solute carrier family 6 member 3 Homo sapiens 66-69 30353564-1 2019 OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). Levodopa 184-190 solute carrier family 6 member 3 Homo sapiens 116-120 30353564-7 2019 CONCLUSIONS: Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients. Levodopa 188-194 solute carrier family 6 member 3 Homo sapiens 107-111 30316985-4 2019 Genotyping of the 40-bp VNTR (rs28363170) and rs393795 (A/C) polymorphisms of the DAT gene was performed in a well-characterized cohort of 181 Italian PD patients in treatment with L-DOPA for 3 years or more. Levodopa 181-187 solute carrier family 6 member 3 Homo sapiens 82-85 30316985-6 2019 However, the combination of the two genotypes 10R/10R (rs28363170) and A carrier (rs393795) of the DAT gene reduces the risk of LID occurrence during long-term therapy with l-DOPA with respect to the PD subjects who did not carry these alleles (OR = 0.31; 95% CI, 0.09-0.88). Levodopa 173-179 solute carrier family 6 member 3 Homo sapiens 99-102 30353564-1 2019 OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). Levodopa 174-182 solute carrier family 6 member 3 Homo sapiens 109-115 30353564-1 2019 OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). Levodopa 174-182 solute carrier family 6 member 3 Homo sapiens 116-120 30353564-1 2019 OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). Levodopa 184-190 solute carrier family 6 member 3 Homo sapiens 109-115 30316985-7 2019 Also based on a logistic regression analysis, the 10R/10R and the A carrier allele of the rs393795 polymorphisms of the DAT gene, could reduce the susceptibility to develop LID during levodopa therapy adjusted by demographical and clinical variables (OR = 0.19; 95% CI, 0.05-0.69). Levodopa 184-192 solute carrier family 6 member 3 Homo sapiens 120-123 29406893-0 2018 Dopamine transporter imaging predicts motor responsiveness to levodopa challenge in patients with Parkinson"s disease: A pilot study of DATSCAN for subthalamic deep brain stimulation. Levodopa 62-70 solute carrier family 6 member 3 Homo sapiens 0-20 27190169-6 2016 Inasmuch as they increase synaptic dopamine levels, dopamine transporter (DAT) inhibitors, whether they are selective or have actions on noradrenaline or serotonin transporters, theoretically represent an attractive way to alleviate parkinsonism per se and potentially enhance l-DOPA antiparkinsonian action (provided that sufficient dopamine terminals remain within the striatum). Levodopa 277-283 solute carrier family 6 member 3 Homo sapiens 52-72 27190169-6 2016 Inasmuch as they increase synaptic dopamine levels, dopamine transporter (DAT) inhibitors, whether they are selective or have actions on noradrenaline or serotonin transporters, theoretically represent an attractive way to alleviate parkinsonism per se and potentially enhance l-DOPA antiparkinsonian action (provided that sufficient dopamine terminals remain within the striatum). Levodopa 277-283 solute carrier family 6 member 3 Homo sapiens 74-77 26642370-0 2016 Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. Levodopa 31-37 solute carrier family 6 member 3 Homo sapiens 58-78 26642370-4 2016 This paper gives an overview on those findings, which, so far, have been obtained on DAT binding in human Parkinson"s disease after treatment with L-DOPA. Levodopa 147-153 solute carrier family 6 member 3 Homo sapiens 85-88 26642370-6 2016 Results indicate that DAT imaging may be reduced in the striata of healthy animals, in the unlesioned striata of animal models of unilateral Parkinson"s disease and in less severly impaired striata of Parkinsonian patients, if animal or human subjects are under acute or subchronic treatment with L-DOPA. Levodopa 297-303 solute carrier family 6 member 3 Homo sapiens 22-25 26253444-10 2015 The serotonin/dopamine transporter ratio might be a potential marker of disease progression and an indicator of risk for levodopa-induced dyskinesia in PD. Levodopa 121-129 solute carrier family 6 member 3 Homo sapiens 14-34 26516604-7 2015 The case highlights the sometimes limited sensitivity of morphologic imaging for identifying the functional consequences of tissue damage and confirms that DaT imaging may serve as a predictor for levodopa responsiveness in Holmes" tremor. Levodopa 197-205 solute carrier family 6 member 3 Homo sapiens 156-159 26253446-0 2015 Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia. Levodopa 55-61 solute carrier family 6 member 3 Homo sapiens 10-30 25805645-4 2015 The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). Levodopa 238-244 solute carrier family 6 member 3 Homo sapiens 127-133 25805645-10 2015 The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. Levodopa 75-81 solute carrier family 6 member 3 Homo sapiens 4-10 25805645-11 2015 The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. Levodopa 130-136 solute carrier family 6 member 3 Homo sapiens 4-10 25805645-13 2015 Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson"s disease. Levodopa 107-113 solute carrier family 6 member 3 Homo sapiens 49-55 24633632-0 2014 Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson"s disease. Levodopa 62-70 solute carrier family 6 member 3 Homo sapiens 21-27 24633632-5 2014 After adjusting for gender, age at PD onset, duration of symptoms prior to levodopa exposure, and multiple testing correction, one SNP in SLC6A3 (with 81 % genotyping success) was significantly associated with LID latency: the C allele of the rs393795 extended the time to LID onset, time ratio = 4.96 (95 % CI, 2.3-10.9; p = 4.1 x 10(-5)). Levodopa 75-83 solute carrier family 6 member 3 Homo sapiens 138-144 23861813-0 2013 DAT1 polymorphism determines L-DOPA effects on learning about others" prosociality. Levodopa 29-35 solute carrier family 6 member 3 Homo sapiens 0-4 24614670-0 2014 Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene. Levodopa 16-24 solute carrier family 6 member 3 Homo sapiens 76-96 24614670-2 2014 METHODS: We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. Levodopa 82-90 solute carrier family 6 member 3 Homo sapiens 118-138 24369987-0 2014 Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Levodopa 92-100 solute carrier family 6 member 3 Homo sapiens 15-35 24369987-10 2014 Functional imaging of the dopamine transporter can be helpful to select this patient sub-group that might benefit from levodopa therapy. Levodopa 119-127 solute carrier family 6 member 3 Homo sapiens 26-46 23631981-1 2013 A previous clinical trial studied the effect of long-term treatment with levodopa (LD) or the dopamine agonist pramipexole (PPX) on disease progression in Parkinson disease using SPECT with the dopamine transporter (DAT)-radioligand [(123)I]beta-CIT as surrogate marker. Levodopa 73-81 solute carrier family 6 member 3 Homo sapiens 194-214 23631981-1 2013 A previous clinical trial studied the effect of long-term treatment with levodopa (LD) or the dopamine agonist pramipexole (PPX) on disease progression in Parkinson disease using SPECT with the dopamine transporter (DAT)-radioligand [(123)I]beta-CIT as surrogate marker. Levodopa 73-81 solute carrier family 6 member 3 Homo sapiens 216-219 23363854-0 2013 Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson"s disease. Levodopa 93-101 solute carrier family 6 member 3 Homo sapiens 21-41 23363854-3 2013 Polymorphisms in the DAT1 gene might affect the reuptake of dopamine in the synaptic cleft, but the influence of this variability on adverse effects or levodopa equivalent dose on PD patients is still poorly investigated. Levodopa 152-160 solute carrier family 6 member 3 Homo sapiens 21-25 23363854-4 2013 Therefore, the aim of the present study was to investigate DAT1 gene polymorphisms on levodopa equivalent dose and visual hallucination occurrence in PD patients. Levodopa 86-94 solute carrier family 6 member 3 Homo sapiens 59-63 23363854-10 2013 Our results support an effect of DAT1 polymorphisms in adverse effects of anti-Parkinsonian drugs and in levodopa equivalent dose usage. Levodopa 105-113 solute carrier family 6 member 3 Homo sapiens 33-37 22531611-12 2012 Significant predictive factors of worst disease severity and negative response to levodopa were hypertension, vascular lesions in basal ganglia/periventricular regions, and normal DAT uptake. Levodopa 82-90 solute carrier family 6 member 3 Homo sapiens 180-183 20457180-8 2010 CONCLUSIONS: Our patients showed two different patterns of clinical and neuroradiological features, that is, atypical parkinsonism with normal DAT density, which is clearly differentiated from PD versus levodopa-responsive parkinsonism with reduced DAT density (classical PD). Levodopa 203-211 solute carrier family 6 member 3 Homo sapiens 143-146 22001994-3 2011 These results demonstrate that levodopa differs from dopamine agonists in its regulation of dopamine transporter expression in peripheral blood lymphocytes. Levodopa 31-39 solute carrier family 6 member 3 Homo sapiens 92-112 21124922-4 2010 METHODOLOGY/PRINCIPAL FINDINGS: We tested the possibility that L-DOPA might interfere with DAT binding. Levodopa 63-69 solute carrier family 6 member 3 Homo sapiens 91-94 20457180-8 2010 CONCLUSIONS: Our patients showed two different patterns of clinical and neuroradiological features, that is, atypical parkinsonism with normal DAT density, which is clearly differentiated from PD versus levodopa-responsive parkinsonism with reduced DAT density (classical PD). Levodopa 203-211 solute carrier family 6 member 3 Homo sapiens 249-252 20199208-4 2010 Treatment with levodopa alone did not change rCBF, whereas it increased basal ganglion DAT activity in the most affected hemisphere. Levodopa 15-23 solute carrier family 6 member 3 Homo sapiens 87-90 20199208-5 2010 Patients who received levodopa and complementary acupuncture had increased rCBF in the frontal lobe, the occipital lobe, the basal ganglion, and the cerebellum in the most affected hemisphere as compared to baseline, but there were no changes in basal ganglia DAT levels. Levodopa 22-30 solute carrier family 6 member 3 Homo sapiens 260-263 16151764-0 2005 The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson"s disease. Levodopa 14-22 solute carrier family 6 member 3 Homo sapiens 34-54 20887875-6 2010 Evaluation of central pharmacokinetics of levodopa action by PET has demonstrated the role of increased synaptic dopamine turnover and downregulation of the dopamine transporter in the pathophysiology of levodopa-induced dyskinesias. Levodopa 42-50 solute carrier family 6 member 3 Homo sapiens 157-177 20887875-6 2010 Evaluation of central pharmacokinetics of levodopa action by PET has demonstrated the role of increased synaptic dopamine turnover and downregulation of the dopamine transporter in the pathophysiology of levodopa-induced dyskinesias. Levodopa 204-212 solute carrier family 6 member 3 Homo sapiens 157-177 17027115-5 2007 Despite no signs of PD, neuro-imaging (DAT-Scan) showed an L-Dopa transducer decrease in putamens. Levodopa 59-65 solute carrier family 6 member 3 Homo sapiens 39-42 16151764-1 2005 PURPOSE: The aim of this study was to evaluate, by means of (123)I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson"s disease. Levodopa 118-126 solute carrier family 6 member 3 Homo sapiens 139-159 16151764-1 2005 PURPOSE: The aim of this study was to evaluate, by means of (123)I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson"s disease. Levodopa 118-126 solute carrier family 6 member 3 Homo sapiens 161-164 16222436-20 2005 However, the beta-CIT SPECT substudy indicates the opposite effect, namely that levodopa causes a more rapid decline in the integrity of the dopamine transporter located in the nigrostriatal nerve terminals in the striatum. Levodopa 80-88 solute carrier family 6 member 3 Homo sapiens 141-161 11402115-0 2001 Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Levodopa 13-19 solute carrier family 6 member 3 Homo sapiens 48-68 12796525-0 2003 L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Levodopa 0-7 solute carrier family 6 member 3 Homo sapiens 42-62 15936832-6 2005 In addition to stimulating D1- and D2-like dopamine receptors, dopamine might also activate adrenoceptors, novel dopamine sites, the dopamine transporter and trace amine receptors, all of which might contribute to the superior effect of L-dopa in Parkinson"s disease. Levodopa 237-243 solute carrier family 6 member 3 Homo sapiens 133-153 12796525-1 2003 OBJECTIVE: To assess whether polymorphisms in the dopamine receptor genes and in the dopamine transporter gene (DAT ) are predictors of adverse effects of L -dopa. Levodopa 155-162 solute carrier family 6 member 3 Homo sapiens 85-105 12796525-1 2003 OBJECTIVE: To assess whether polymorphisms in the dopamine receptor genes and in the dopamine transporter gene (DAT ) are predictors of adverse effects of L -dopa. Levodopa 155-162 solute carrier family 6 member 3 Homo sapiens 112-115 12796525-9 2003 However, the nine copy allele 40-bp VNTR of the DAT is a predictor for the occurrence of psychosis or dyskinesia in L -dopa-treated patients. Levodopa 116-123 solute carrier family 6 member 3 Homo sapiens 48-51 12480442-11 2002 This work has been criticised as the SPECT results may have resulted from a differential effect of the agonist and levodopa on the regulation of the dopamine transporter, thereby influencing the imaging outcome measure. Levodopa 115-123 solute carrier family 6 member 3 Homo sapiens 149-169 11402115-3 2001 METHODS: A randomized, assessor-blinded, placebo-controlled clinical trial was performed in subjects with early PD to determine whether L-dopa or pramipexole might regulate striatal DAT binding as measured by PET with [(11)C]RTI-32. Levodopa 136-142 solute carrier family 6 member 3 Homo sapiens 182-185 11402115-5 2001 RESULTS: Mean interval change in DAT binding was significantly reduced by 16% to 22% in all striatal regions (caudate, anterior and posterior putamen) of the L-dopa-treated patients, whereas significant changes in the pramipexole-treated patients were limited to the contralateral caudate (-15%), ipsilateral anterior putamen (-14%), and posterior putamen (-20%). Levodopa 158-164 solute carrier family 6 member 3 Homo sapiens 33-36 11402115-8 2001 CONCLUSIONS: Short-term therapy with L-dopa and, to a lesser extent, pramipexole can modestly down-regulate striatal DAT in patients with early PD. Levodopa 37-43 solute carrier family 6 member 3 Homo sapiens 117-120 10348466-1 1999 The effect of subchronic treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson"s disease with SPECT (single photon emission computed tomography) using [123I]beta-CIT (2beta-carbomethoxy-3beta-[4-iodophenyl]tropane) as the radiotracer. Levodopa 40-46 solute carrier family 6 member 3 Homo sapiens 85-106 11083235-0 2000 Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. Levodopa 30-38 solute carrier family 6 member 3 Homo sapiens 42-62 11083235-1 2000 The objective of this article was to study the reproducibility and effect of levodopa on dopamine transporter function measurements using 2beta-carbomethoxy-3beta-(4-[18F]fluorophenyl)tropane ([18F]CFT) positron emission tomography (PET). Levodopa 77-85 solute carrier family 6 member 3 Homo sapiens 89-109 10995853-2 2000 l-3,4-Dihydroxyphenylalanine (l-[beta-(11)C]DOPA) and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane ([beta-(11)C]CFT) were used to measure dopamine synthesis rate and dopamine transporter (DAT) availability, respectively. Levodopa 0-28 solute carrier family 6 member 3 Homo sapiens 170-190 10995853-2 2000 l-3,4-Dihydroxyphenylalanine (l-[beta-(11)C]DOPA) and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane ([beta-(11)C]CFT) were used to measure dopamine synthesis rate and dopamine transporter (DAT) availability, respectively. Levodopa 0-28 solute carrier family 6 member 3 Homo sapiens 192-195 11072750-14 2000 All patients were treated with L-DOPA and those given a higher dose showed a more rapid decrease of dopamine transporter density. Levodopa 31-37 solute carrier family 6 member 3 Homo sapiens 100-120 10214747-3 1999 Regional striatal dopamine transporter binding was measured in the caudate, anterior putamen, and posterior putamen of six patients with L-dopa-responsive stage 2 PD, six patients with PSP, and six age-comparable healthy controls. Levodopa 137-143 solute carrier family 6 member 3 Homo sapiens 18-38 10348466-1 1999 The effect of subchronic treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson"s disease with SPECT (single photon emission computed tomography) using [123I]beta-CIT (2beta-carbomethoxy-3beta-[4-iodophenyl]tropane) as the radiotracer. Levodopa 40-46 solute carrier family 6 member 3 Homo sapiens 108-111 9191769-1 1997 To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson"s disease (PD), we employed [11C]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. Levodopa 203-209 solute carrier family 6 member 3 Homo sapiens 151-171 10086151-2 1999 Limitations of levodopa therapy have led to development of numerous therapeutic approaches at the level of levodopa/dopamine metabolism, dopamine receptors, dopamine transporter, and other neurotransmitter systems. Levodopa 15-23 solute carrier family 6 member 3 Homo sapiens 157-177 29185545-3 2017 A community service-based longitudinal study showed that dopamine transporter imaging could help identify subgroups of patients with parkinsonism associated with antipsychotics with a progressive course, potentially manageable with l-dopa. Levodopa 232-238 solute carrier family 6 member 3 Homo sapiens 57-77 34582053-7 2022 Cutaneous P-SYN and abnormal DAT scans were noted in the 4 levodopa-responsive patients and 1 asymptomatic patient. Levodopa 59-67 solute carrier family 6 member 3 Homo sapiens 29-32 35508570-0 2022 Marked response to levodopa in a patient with multiple system atrophy presenting with orthostatic hypotension: should reduced DAT uptake on DaTSCAN be a criterion for response to levodopa? Levodopa 19-27 solute carrier family 6 member 3 Homo sapiens 126-129 34284020-0 2021 L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. Levodopa 0-6 solute carrier family 6 member 3 Homo sapiens 79-99 35508570-0 2022 Marked response to levodopa in a patient with multiple system atrophy presenting with orthostatic hypotension: should reduced DAT uptake on DaTSCAN be a criterion for response to levodopa? Levodopa 179-187 solute carrier family 6 member 3 Homo sapiens 126-129 33962918-2 2021 GTP cyclohydrolase 1 (GCH-1) deficiency, which triggers pteridine hypometabolism and normally develops in childhood, can mediate an adult-onset decrease in levodopa production and dopa-responsive dystonia (DRD), with normal dopamine transporter single-photon emission computed tomography (DAT-SPECT). Levodopa 156-164 solute carrier family 6 member 3 Homo sapiens 224-244 32520511-2 2020 The neurologist decided to perform dopamine transporter imaging (F-FP-CIT PET/CT) for accurate diagnosis, taking into account the potential adverse effects of L-dopa that the patient had been taking for a long time. Levodopa 159-165 solute carrier family 6 member 3 Homo sapiens 35-55